Key result
Most experimental ischemic stroke therapies fail in trials, leaving IV thrombolysis and citicoline as exceptions.
Answers are grounded in this paper and cite their sources.
Undeniable advances have been made in clinical and experimental investigation into the pathophysiology, diagnosis, and treatment of cerebral ischemia. However, with the exception of intravenous thrombolysis and some neuroprotectors, such as citicoline, the majority of the drugs successfully tested in experimental studies have failed in clinical trials. Valuable lessons for the improvement of research methodology and appropriate coordination of experimental and clinical research can be learnt from the analysis of discrepancies between the laboratory and clinic, which will allow us to increase the power and cost-effectiveness of the studies. In addition, this progress has opened the way for the investigation of very promising new therapeutic strategies, such as combined pharmacological and mechanical thrombolysis, thrombolysis and neuroprotection, or the combination of various neuroprotectors, antiapoptotic therapies, and neurorestoration therapies, such as stem cell transplants.
No takes yet. Share an insight, caveat, or question.
Díez‐Tejedor et al. (2005) conducted a review in Ischemic stroke / cerebral ischemia. Ischemic stroke therapies (thrombolysis, neuroprotectors, stem cell transplants) was evaluated. Experimental ischemic stroke therapies largely fail in clinical trials except IV thrombolysis and citicoline, prompting combined thrombolytic and neurorestorative strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: